Breviscapine ameliorates CCl₄-induced liver injury in mice through inhibiting inflammatory apoptotic response and ROS generation

YU LIU, PEI-HAO WEN, XIN-XUE ZHANG, YANG DAI and QIANG HE

Department of Hepatobiliary Surgery, Beijing Chao-Yang Hospital Affiliated to Capital University of Medical Science, Beijing 100000, P.R. China

Received May 28, 2017; Accepted April 5, 2018

DOI: 10.3892/ijmm.2018.3651

Abstract. Acute liver injury is characterized by fibrosis, inflammation and apoptosis, leading to liver failure, cirrhosis or cancer and affecting the clinical outcome in the long term. However, no effective therapeutic strategy is currently available. Breviscapine, a mixture of flavonoid glycosides, has been reported to have multiple biological functions. The present study aimed to investigate the effects of breviscapine on acute liver injury induced by CCl₄ in mice. C57BL/6 mice were subjected to intraperitoneal injection with CCl₄ for 8 weeks with or without breviscapine (15 or 30 mg/kg). Mice treated with CCl₄ developed acute liver injury, as evidenced by histological analysis, Masson trichrome and Sirius Red staining, accompanied with elevated levels of alanine amino-transferase and aspartate aminotransferase. Furthermore, increases in pro-inflammatory cytokines, chemokines and apoptotic factors, including caspase-3 and poly(ADP ribose) polymerase-2 (PARP-2), were observed. Breviscapine treatment significantly and dose-dependently reduced collagen deposition and the fibrotic area. Inflammatory cytokines were downregulated by breviscapine through inactivating Toll-like receptor 4/nuclear factor-κB signaling pathways. In addition, co-administration of breviscapine with CCl₄ decreased the apoptotic response by enhancing B-cell lymphoma-2 (Bcl-2) levels, while reducing Bcl-2-associated X protein, apoptotic protease activating factor 1, caspase-3 and PARP activity. Furthermore, CCl₄-induced oxidative stress was blocked by breviscapine through improving anti-oxidants and impeding mitogen-activated protein kinase pathways. The present study highlighted that breviscapine exhibited liver-protective effects against acute hepatic injury induced by CCl₄ via suppressing inflammation and apoptosis.

Introduction

The liver is known as the primary organ important for drug and chemical substance metabolism (1). Liver injury may be induced by drug abuse, viral infection and heavy alcohol consumption, and is considered to be a common clinical disease (2,3). CCl₄ is a well-known hepatotoxin, which may induce liver injury through various mechanisms, including oxidative stress, inflammatory response and apoptosis (4,5). The CCl₄-induced animal model of acute liver injury is well established, leading to fibrosis, inflammation and apoptotic response in mice (6). Previous studies have assessed the possible molecular mechanism of liver toxicity induced by CCl₄ (7,8). Certain hepatoprotective agents have been investigated and applied in clinical practice, but a large proportion of them have potential adverse effects (9,10). Therefore, application of natural products isolated from plants as an effective and safe therapeutic strategy for liver disease has been in the focus of recent research (11,12).

Breviscapine (Fig. 1A) is a mixture of flavonoid glycosides isolated from Chinese herbs, including Erigeron breviscapus (Vant.) (13). Breviscapine has been reported to have various biological activities, including anti-oxidant, anticancer, anti-degenerative and anti-angiogenesis effects (14-16). It has been indicated that breviscapine administration is safe and has low toxicity to various normal cell types (17,18). In addition, the anti-inflammatory effect of breviscapine has been reported (16). Accordingly, breviscapine is extensively used for the treatment of cerebrovascular diseases caused by cerebral infarction, hypertension and chronic arachnoiditis along with their sequelae, and is suggested to inhibit tumor proliferation and angiogenesis, thereby limiting tumor development (19). However, the effects of breviscapine on liver injury and the underlying molecular mechanisms still remain to be fully elucidated.

The present study attempted to investigate whether breviscapine may be effectively used as a therapeutic drug, and to test this, it was administered to mice with CCl₄-induced liver injury and L02 cells challenged with lipopolysaccharide (LPS).
It was indicated that inflammatory cytokines were downregulated by breviscapine through inactivating the Toll-like receptor (TLR)4/nuclear factor (NF)-kB signaling pathways. Breviscapine co-administered with CCl4 reduced apoptosis by inactivating the caspase-3 signaling pathway. In addition, CCl4-induced oxidative stress was blocked by breviscapine through improving anti-oxidants and impeding mitogen-activated protein kinase (MAPK) signaling. The present study indicated that breviscapine exerted protective effects against acute liver injury by suppressing inflammation, apoptosis and oxidative stress, which may be used as a therapeutic strategy for patients with liver injury.

Materials and methods

Reagents. CCl4 was obtained from Tianjin Baishi Chemical (Tianjin, China). A Cell Counting Kit-8 (CCK-8) was purchased from Beyotime Institute of Biotechnology (Shanghai, China). Breviscapine (purity, ≥98%) and Picrosirius red were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Antibodies to B-cell lymphoma-2 (Bcl-2)-associated X protein (Bax; cat. no. 2772; 1:1,000 dilution), Bcl-2 (cat. no. 3498; 1:1,000 dilution), myeloid differentiation primary response gene 8 (MyD88; cat. no. 4283; 1:1,000 dilution), phospho (p)-NF-kB (cat. no. 3033; 1:1,000 dilution), NF-kB (cat. no. 8242; 1:1,000 dilution), phospho-inhibitor of NF-kB (p-IkBα; cat. no. 2859; 1:1,000 dilution), phospho-IkB kinase α (p-IKKα; cat. no. 2078; 1:1,000 dilution), extracellular signal-regulated kinase (ERK)1/2 (cat. no. 4377; 1:1,000 dilution) p-ERK1/2 (cat. no. 9101; 1:1,000 dilution), p38 (cat. no. 8690; 1:1,000 dilution), p-p38 (cat. no. 9215; 1:1,000 dilution), superoxide dismutase (SOD1; cat. no. 13141; 1:1,000 dilution) and GAPDH (cat. no. 5174; 1:1,000 dilution), all raised in rabbit, were obtained from Cell Signaling Technology Inc. (Danvers, MA, USA). Antibodies against Toll-like receptor (TLR)4 (cat. no. ab13556; 1:1,000 dilution), c-Jun N-terminal kinase (JNK; cat. no. ab4821; 1:1,000 dilution), p-JNK (cat. no. ab47337; 1:1,000 dilution), nuclear factor erythroid 2-related factor 2 (Nrf2; cat. no. ab62522; 1:1,000 dilution), heme oxygenase (HO)-1 (cat. no. ab13248; 1:1,000 dilution), NAD(P)H quinone dehydrogenase-1 (NQO-1; cat. no. ab34173; 1:1000 dilution) activated caspase-3 (cat. no. ab52293; 1:1,000 dilution), pro-caspase-3 (cat. no. ab90437; 1:1,000 dilution), cleaved poly(ADP-ribose) polymerase (PARP; cat. no. ab13907; 1:1,000 dilution), PARP (cat. no. ab218132; 1:1,000 dilution) and apopptotic protease activating factor-1 (Apaf-1; cat. no. ab2000; 1:1,000 dilution), all raised in rabbit, were purchased from Abcam (Cambridge, MA, USA). A HRP-labelled secondary antibody (cat. no. KIT-5902; 1:200 dilution; Max Vision HRP-polymer anti-rabbit IHC kit) was purchased from Maxim Biotechnology Co., Ltd. (Fuzhou, China).

Animals and treatments. A total of 40 healthy male C57BL/6 mice (age, 6-8 weeks, weight, 20-22 g), were purchased from Shanghai Experimental Animal Center (Shanghai, China) and kept under standard conditions of 25±2°C and 50±10% humidity with a 12-h light/dark cycle with food and water provided ad libitum in cages. The experimental protocols, which were in accordance with the Guide for the Care and Use of Experimental Animals of the National Institutes of Health (NIH) from 1996 (20) and were approved by the Institutional Animal Care and Use Committee of the Beijing Chao-Yang Hospital (Beijing, China). Prior to experimental treatment, all mice were kept under the standard conditions for 1 week for adaptation. Next, the mice were divided into four groups (n=10 each): i) Control group (Con); ii) CCl4-treated model group (Mod); iii) CCl4 and breviscapine co-treatment (15 mg/kg) and iv) CCl4 and breviscapine co-treatment (30 mg/kg). A total of 30 mice were treated twice a week with 8 consecutive intraperitoneal (i.p.) injections of 1 ml/kg CCl4 (diluted at 1:10 in olive oil) to induce liver fibrosis. As for the breviscapine-treated groups, 15 or 30 mg/kg breviscapine was administered to the mice each day by oral gavage (Fig. 1B) for 8 weeks. At the end of the experiment, blood samples and liver tissues were collected from the mice for further assays.

Cell culture and treatment. The L02 human normal liver cell line was purchased from KeyGEN BioTECH (Nanjing, China). The BRL-3A rat normal liver line and the AML-12 mouse normal liver cell line were all purchased from the cell bank of the Chinese Academy of Sciences (Shanghai, China). All cells were cultured and grown in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum (both from Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml penicillin and 100 mg/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO2. The cells were then exposed to LPS (100 ng/ml) for 24 h in the absence or presence of breviscapine at different concentrations (20 and 40 μM) (21-24).

Cell viability assessment. L02 cells were seeded in a 96-well plate at 1×104 cells/well overnight, prior to the addition of breviscapine. The cells were treated with various concentrations of breviscapine (0, 5, 10, 20 and 40 μM) for different durations ranging from 0-72 h (0, 6, 12, 24, 36, 48 and 72 h) in the absence of LPS. Subsequently, 10 μl CCK-8 solution (Dojindo Laboratories, Kumamoto, Japan) was added to each well and the plate was incubated at 37°C for 1 h. Finally, the absorbance at 450 nm was measured to determine the cell viability. The protocol was performed according to the manufacturer's protocols.

Analysis of biochemical indicators. To evaluate liver injury, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were determined using ALT and AST reagent kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to manufacturer's protocols. Albumin levels in the serum were measured by using an albumin reagent kit (Nanjing JianCheng Bioengineering Institute). As for the hepatic hydroxyproline content, 200 mg Snap-frozen liver specimens were weighed and hydrolyzed in NaOH (2 M). The hydroxyproline content was quantified following the manufacturer's instructions of the hydroxyproline measurement kit (Nanjing Jiancheng Bioengineering Institute). SOD, glutathione (GSH), malondialdehyde (MDA), H2O2 and myeloperoxidase (MPO) levels were measured using the standard diagnostic kits purchased from NanJing JianCheng Bioengineering Institute.

ELISA. The levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and monocyte chemotractant protein (MCP)-1
in serum and liver tissue samples were determined by using the ELISA kits purchased from R&D systems (Minneapolis, MN, USA) following the manufacturer's protocols.

**Terminal deoxynucleotidyl transferase deoxyuridinetriphosphate nick end labelling (TUNEL) analysis.** TUNEL analysis was used to indicate apoptosis in the liver tissue samples. The assay detects the 3' hydroxyl ends of DNA fragments. The staining was performed with the *In Situ* Cell Death Detection kit (TUNEL assay; KeyGen Biotech; Nanjing, China) following the manufacturer's protocols. Recombinant DNase I (Takara Biotechnology Co., Ltd., Dalian, China) was included in the positive control. The immunostained liver cells of were quantified using a light microscope and results are presented as a percentage of the control.

**Assessment of reactive oxygen species (ROS) generation.** A 5-µM intracellular probe of non-fluorescent 2',7'-dichlorofluorescein-diacetate (DCFH-DA; KeyGen Biotech) was used to detect the cellular ROS formation. The L02 cells (5x10⁵ cells/well) were treated with LPS (100 ng/ml) with or without breviscapine for 24 h. DCFH-DA was then added and the cells were cultured continuously in the dark at 37°C for 20 min. Subsequently, the fluorescent cells were visualized using a fluorescence microscope.

**Immunofluorescent staining.** For *in vivo* analysis, the frozen liver sections were blocked using a solution containing 4% normal goat serum (OriGene Technologies, Inc., Rockville, MD, USA), 1% Triton X-100 and 1% bovine serum albumin (Xi'an Guanyu Bio-Tech Co., Ltd., Xi'an, China) for 1 h at the room temperature. Next, the sections were incubated with anti-TLR4 primary antibody (1:100 dilution) at 4°C overnight. Subsequently, they were washed three times with PBS (0.1 M) containing 0.5% Triton X-100 for 5 min each time, and the sections were then incubated with Alexa Fluor 594-labeled anti-rabbit secondary antibody (cat. no. A-11072; 1:500 dilution; Invitrogen; Thermo Fisher Scientific, Inc.) at room temperature for 1 h prior to analysis with a fluorescence microscope equipped with a digital camera. Finally, the fluorescent cells were quantified.

**In vitro,** the L02 cells were washed three times with chilled PBS and fixed with 3.7% (v/v) formaldehyde in PBS for 15 min. The specimens were then permeabilized for 5 min using 0.1% Triton X-100. For Apaf-1 fluorescence staining, 50 µg/ml mouse anti-Apaf-1 antibody was applied and incubated at 4°C overnight, followed by staining with anti-mouse secondary antibody labelled with Alexa Fluor 488 (cat. no. A-21441; 1:500 dilution; Invitrogen; Thermo Fisher Scientific, Inc.) for 30 min. Subsequent to washing in PBS for 3 times, the immunofluorescence was visualized and quantified with a Zeiss
**Immunohistological analysis.** The liver tissue samples obtained from mice were fixed in 4% paraformaldehyde, embedded in paraffin, sectioned at 4 µm and then stained with haematoxylin and eosin (H&E) for 10 min or Masson's trichrome blue for 5 min at room temperature to analyze the liver injury and collagen deposition, respectively. The score of injured level was described in a previous study (25). The sections stained with Masson's trichrome were scanned and analyzed with a digital image analyzer (Image-Pro Analyzer 7 software; Media Cybernetics, Inc., Rockville, MD, USA). Sirius red staining was also used to calculate the fibrotic area. In brief, the liver sections were incubated with picrosirius red for 2 h at room temperature and then washed with acetic acid and water. The percentage of the fibrotic area was calculated in 5 randomly selected fields per slide. Furthermore, liver tissue samples were also subjected to immunohistochemical staining for the assessment of Bax and Apaf-1 expression. The sections were stained with rabbit anti-Bax (1:200 dilution) or rabbit anti-Apaf-1 (1:200 dilution) at 4˚C overnight. Slides were incubated in a humidified chamber for 1 h and then incubated for 10 min with a HRP-labelled secondary antibody (Max Vision HRP-polymer anti-rabbit IHC kit, 1:200 dilution) or rabbit anti-Apaf-1 (1:200 dilution) at room temperature. Immunoreactive proteins were visualized using a DAB substrate (cat. no. SK-4100; Vector Laboratories, Inc., Burlingame, CA, USA), followed by counterstaining with haematoxylin at room temperature for 50 min. Immunohistochemical quantification was carried out using image analysis software (ImageJ; 1.46a; National Institutes of Health, Bethesda, MD, USA). The histological protocol was in line with standard procedures (26,27).

**Western blot analysis.** The liver tissues and L02 cells were homogenized with 10% (wt/vol) hypertonic buffer (1 mM EDTA, 1 mM Pefabloc SC (Roche Applied Science, Penzberg, Germany), 5 µg/ml leupeptin, 25 mM Tris-HCl, 5 µg/ml soybean trypsin inhibitor (Sigma-Aldrich; Merck KGaA), 4 mM benzamidine and 50 µg/ml aprotinin; pH 8.0). The final supernatants were obtained by centrifugation at 12,000 x g rpm for 20 min. The protein concentration was determined using a bicinchoninic acid protein assay kit (Thermo Fisher Scientific, Inc.) with bovine serum albumin as a standard. Equal amounts (20-40 µg) of total protein were subjected to 10 or 12% SDS-PAGE and electrophoretically transferred to the polyvinylidene difluoride membranes (Merck KGaA). The membranes were then blocked with 5% skim milk Tris buffered saline with 0.1% Tween-20 (TBST), washed, and then incubated with primary antibodies (Bax, Bcl-2, MyD88, p-ERK1/2, p-ERK1/2, p-JNK, p-JNK, p-p38, SOD1, GAPDH, TLR4, INK, Nrf2, HO-1, NQO-1, activated caspase-3, pro-caspase-3, PARP, Apaf-1) overnight at 4˚C. Then, the membrane was washed with TBST three times, followed by incubation with a horseradish peroxidase (HRP)-conjugated secondary antibody (cat. no. ab191866; 1:2,500 dilution; Abcam) at room temperature for 2 h. Western blot bands were observed using a GE Healthcare ECL Western Blotting Analysis System (GE Healthcare, Little Chalfont, UK) and exposed to X-ray film (Eastman Kodak, Rochester NY, USA). For enhanced chemiluminescence, detection reagents A and B were mixed at a 1:1 ratio, which was immediately added to the blotting membrane. In total, 0.125 ml working solution was used per cm² for each membrane. The blot was incubated for 1 min at room temperature and excess reagents were drained. The blot was then exposed to X-ray film. The protein expression levels were defined as the grey value determined with ImageJ software version 1.4.2b (NIH, Bethesda, MD, USA) and standardized by presenting them as a fold of the housekeeping gene GAPDH as the control.

**Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).** Total RNA was extracted from tissues and cells with the TRI Reagent (Sigma-Aldrich; Merck KGaA) following the manufacturer’s instructions and treated with deoxyribonuclease I (Roche Applied Science). The mRNA was then reverse transcribed to complementary DNA using the miScript II RT kit (Qiagen, Hilden, Germany), which was then amplified and quantified by real-time qPCR using All-in-One qPCR Mix (GeneCopoeia, Inc., Rockville, MD, USA) in a 20 µl reaction volume containing 10 µl of 2X All-in-One qPCR Mix (GeneCopoeia, Inc.), 1 µl of 2 µM forward primer, 1 µl of 2 µM reverse primer, 1 µl of cDNA, and 6 µl of nuclease-free water. The thermocycling conditions were for 35 cycles of 95˚C for 20 sec, 54˚C for 30 sec and 72˚C for 30 sec according to a previous study (28). Fold changes in mRNA levels of target genes relative to the endogenous control GAPDH were calculated. In brief, the Cq method was used for quantification cycle values of each target gene were subtracted from the Ct values of the housekeeping gene GAPDH (ΔCt). Target gene ΔΔCt was calculated as ΔCt of the target gene minus the ΔCt of the control. The fold expression change in mRNA expression was calculated as 2-ΔΔCt (29). The primer sequences (5'-3') were as follows: TNF-α forward, CAAGAG AGTAGGGAAGTGG and reverse, AGCAGAAACGCCGGACT AGCTAAC; IL-1β forward, AGAAAGATAGCAGTGACC and reverse, CGTTCTGAATACTTTGGAGC; IL-6 forward, GAGACCGCAGCGTGAGAC and reverse, CGGAAGATGA AGAGGCACACT; IL-18 forward, TGACTGATACGCA GTCACG and reverse, TGCTCAAAGGCAATGTTAATCC; Bcl-2 forward, GATGGATCATGACAGAGGACA and reverse, TCAACAGCTAGATATGTG; Bax forward, AACAGA GACATAAAGGGCGCTAC and reverse, CACTACCATAG GGTGCCCTAT; Apaf-1 forward, TCGTGAAGACCTCAA GAGCC and reverse, TCTGCTACATTCAAGGCTGCAA; GAPDH forward, AGGAACCGAGTTCGCACTCGAA and reverse, TCAACACCTACAGCACAACGAG.

**Statistical analysis.** Values are expressed as the mean ± standard error of the mean. Statistical analyses were performed using GraphPad Prism version 6.0 (Graph Pad Software, Inc., La Jolla, CA, USA). Analysis of variance followed by Dunnett's least-significant differences post-hoc test was performed for comparison between groups. P<0.05 was considered to indicate a statistically significant difference.

**Results**

Breviscapine improves CCl₄-induced histological changes and collagen deposition in mice. CCl₄ is well-known to cause hepatic injury, apoptosis and necrosis (4,5). In order to investigate the...
effects of breviscapine on hepatic damage, male mice were subjected to a 8-week treatment with CCl₄ with optional co-treatment with 15 or 30 mg/kg breviscapine. H&E staining indicated that CCl₄ treatment produced liver injury, resulting in higher histological score compared with those in the control group. Of note, breviscapine administration ameliorated liver injury induced by CCl₄, resulting in lower histological score compared with those in the Mod group (Fig. 1C). In addition, CCl₄ treatment generated higher collagen accumulation, as indicated by Masson trichrome staining, which was reduced by breviscapine administration (Fig. 1D). Finally, Sirius Red staining indicated that marked fibrosis occurred in the CCl₄-treated group. However, breviscapine reduced the fibrotic area in the liver tissue of CCl₄-induced mice (Fig. 1E). These results indicated that breviscapine administration significantly attenuated CCl₄-induced liver damage.

Breviscapine attenuates liver injury in mice induced by CCl₄. To further clarify the therapeutic effect of breviscapine on liver injury induced by CCl₄, serum ALT, AST, albumin and liver hydroxyproline were calculated. As presented in Fig. 2A and B, respectively, ALT and AST levels in the serum were markedly elevated in the CCl₄-group compared with those in the control group, while breviscapine significantly decreased the ALT and AST levels in a dose-dependent manner. As for albumin, no significant difference was observed among the four groups (Fig. 2C). Furthermore, hydroxyproline levels in the liver were markedly increased after CCl₄ treatment. However, breviscapine administration reduced the hydroxyproline levels in comparison to those in the CCl₄-treated group (Fig. 2D). These results indicated that breviscapine had preventive effects against liver injury caused by CCl₄ treatment.

Breviscapine ameliorates CCl₄-induced liver injury by reducing pro-inflammatory cytokine secretion. The levels of TNF-α, IL-6, IL-1β and MCP-1 in the liver tissues were also elevated after CCl₄ treatment, which was inhibited by breviscapine administration, as determined by ELISA (Fig. 3A). In addition, the circulating pro-inflammatory cytokines TNF-α, IL-6 and IL-1β, as well as the chemokine MCP-1, were assessed.

Figure 2. Breviscapine attenuates liver injury in mice induced by CCl₄. (A) ALT, (B) AST and (C) Albumin levels in the serum of mice were examined to assess the effect of breviscapine in regulating liver injury induced by CCl₄. (D) Liver hydroxyproline levels were assessed. Values are expressed as the mean ± standard error of the mean (n=10). ***P<0.001 vs. Con; **P<0.01 and +++P<0.001 vs. CCl₄-treated mice. Mod, CCl₄-treated group; Con, control group; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Figure 3. Breviscapine ameliorates CCl₄-induced liver injury by reducing pro-inflammatory cytokine secretion. (A) Serum pro-inflammatory cytokines TNF-α, IL-6 and IL-1β and chemokine of MCP-1 were determined using ELISA kits. (B) Liver pro-inflammatory cytokines TNF-α, IL-6 and IL-1β and chemokine MCP-1 were determined using commercial ELISA kits. Values are expressed as the mean ± standard error of the mean (n=10). **P<0.01 and ***P<0.001 vs. Con; *P<0.05, **P<0.01 and ***P<0.001 vs. CCl₄-induced mice. Mod, CCl₄-treated group; Con, control group; TNF, tumor necrosis factor; IL, interleukin; MCP, monocyte chemoattractant protein.
LIU et al: BREVISCAPINE AMELIORATES CCL\textsubscript{4}-INDUCED LIVER INJURY

by ELISA (Fig. 3B). Compared with those in the control group, the serum levels of TNF-\(\alpha\), IL-6, IL-1\(\beta\) and MCP-1 were markedly elevated in the CCl\textsubscript{4}-treated group. However, mice treated with breviscapine exhibited a significant downregulation of TNF-\(\alpha\), IL-6, IL-1\(\beta\) and MCP-1 levels in the serum. Taken together, the results indicated that breviscapine suppressed the secretion of pro-inflammatory cytokines and chemokines in serum and their expression in liver tissues.

The attenuation of CCL\textsubscript{4}-induced liver injury by breviscapine proceeds via suppression of TLR4/NF-\(\kappa\)B signaling. According to previous studies, TLR4 is involved in liver injury induced by CCL\textsubscript{4}, initiating the inflammatory response by stimulating NF-\(\kappa\)B activity (30). To determine whether breviscapine exerted its protective effects against CCL\textsubscript{4}-induced liver injury by suppressing inflammation via TLR4/NF-\(\kappa\)B signaling, immunofluorescence and western blot analyses were used to determine the expression of TLR4 and NF-\(\kappa\)B pathway components. Immunofluorescence staining indicated that TLR4 was significantly upregulated in the liver tissue samples of mice induced with CCL\textsubscript{4}, when compared with those in the control group (Fig. 4A). The number TLR4-positive cells was markedly decreased in breviscapine-treated mice, when compared with that in the CCl\textsubscript{4} group. To further explore the mechanistic involvement of the TLR4 signaling pathway, TLR4 and its downstream signaling molecule MyD88 were assessed by western blot analysis. As presented in Fig. 4B, a significant increase in TLR4 and MyD88 expression levels was observed in the CCl\textsubscript{4} vs. the control group. However, breviscapine-treated mice exhibited reduced TLR4 and MyD88 protein levels compared with those in the CCl\textsubscript{4} group. Next, the NF-\(\kappa\)B signaling pathway was examined. As indicated in Fig. 4C, mice subjected to CCL\textsubscript{4} treatment had higher levels of phosphorylated IKK\(\alpha\), I\(\kappa\)B\(\alpha\) and NF-\(\kappa\)B, while breviscapine-treated mice showed reduced levels of these proteins compared with those in the control group. Of note, IKK\(\alpha\), I\(\kappa\)B\(\alpha\) and NF-\(\kappa\)B...
activation were downregulated in breviscapine-treated mice subjected to CCl4 treatment, compared with those in mice only treated with CCl4. In conclusion, the results demonstrated that breviscapine administration de-activated the TLR4/NF-κB signaling pathway in CCl4-treated mice.

**Breviscapine attenuates liver injury by inhibiting apoptosis in CCl4-induced mice.** To determine whether CCl4 caused apoptosis, the expression levels of apoptosis-associated molecules were determined. CCl4 treatment markedly increased the mRNA levels of the pro-apoptotic mitochondrial protein Bax, which was decreased when the mice were co-treated with breviscapine (Fig. 5A). In addition, western blot analysis indicated that the expression levels of the anti-apoptotic molecule Bcl-2 exhibited an opposite trend to that of the protein expression levels of Bax in the CCl4-treated mice, indicating that CCl4 induced apoptosis in the liver tissue samples. Of note, breviscapine treatment caused a significant upregulation of Bcl-2 expression to prevent apoptosis (Fig. 5B). Finally, caspase-3 and PARP were determined by western blot to further clarify the role of breviscapine in CCl4-induced apoptosis. As presented in Fig. 5C, active caspase-3 and PARP were increased in the CCl4-treated group in comparison with the control group, while breviscapine had a suppressive effect on caspase-3 and PARP cleavage.

In addition, TUNEL analysis was performed to further evaluate cellular apoptosis. The representative images and the histogram in Fig. 6A confirmed that CCl4 induced massive apoptosis, while breviscapine administration significantly reduced the amount of TUNEL-positive cells. Apaf-1 is important during caspase-dependent mitochondrial apoptosis (31). As indicated in Fig. 6B, Apaf-1 was significantly upregulated following CCl4 treatment, while breviscapine administration reduced Apaf-1 protein levels to inhibit apoptosis. These results indicated that breviscapine attenuated CCl4-induced liver injury by suppressing the apoptotic response.

**Breviscapine reduces oxidative stress in the livers of mice treated with CCl4.** Oxidative stress is another essential factor contributing to acute liver injury (32,33). Thus, the present study further explored whether breviscapine modulates oxidative stress to attenuate liver injury induced by CCl4 in vivo. As presented in Fig. 7A, liver tissue samples of mice from the CCl4 group exhibited reduced levels of the anti-oxidants SOD and GSH, which were comparable to those in the Con group. Breviscapine significantly upregulated SOD activity and GSH levels in liver tissues. By contrast, MDA and H2O2 levels were enhanced by CCl4 treatment, but were downregulated after breviscapine administration. Furthermore, western
blot analysis indicated that the CCl₄-induced decrease of anti-oxidants, including SOD1, HO-1, NQO-1 and Nrf2, was inhibited by treatment with breviscapine (Fig. 7B). MAPK signaling is closely associated with the progression of oxidative stress (34,35). The ratios of phosphorylated p38, ERK1/2 and JNK vs. total proteins are shown. As presented in Fig. 7C, p38, ERK1/2 and JNK were phosphorylated by CCl₄ stimulation, and breviscapine inhibited the activation of these MAPKs. Therefore, the above results indicated that breviscapine reduced oxidative stress to alleviate liver injury induced by CCl₄.

Breviscapine downregulates the LPS-induced inflammatory response in L02 cells in vitro. In order to further confirm the effects of breviscapine on liver injury, an in vitro experiment was performed. First, the viability of liver cell lines was examined by CCK-8 analysis. As presented in Fig. 8A, the normal liver cell lines L02, BRL-3A and AML-12 were treated with various concentrations of breviscapine (0, 5, 10, 20 and 40 µM) for different durations ranging from 0-72 h. The cell viability assay indicated that the above treatment had almost no significant effect on normal liver cell lines, except for the BRL-3A cells treated with breviscapine at 40 µM for 72 h. Therefore, it was suggested that breviscapine is safe for application, exerting only little cytotoxicity to normal liver cell lines isolated from a human, rat and mouse. In the next experiment, L02 cells were treated with 100 ng/ml LPS for 24 h, in

Figure 6. Breviscapine reduces apoptosis the liver of mice treated with CCl₄. (A) TUNEL analysis was used to assess apoptosis in CCl₄-induced livers in mice after Breviscapine administration. Scale bar, 100 µm. (B) Apaf-1 positive cells were calculated in the liver sections of mice. Scale bar, 100 µm. Values are expressed as the mean ± standard error of the mean (n=10). **P<0.01 vs. Con; ***P<0.001 vs. Con; ++P<0.01 and +++P<0.001 vs. CCl₄-induced mice. Mod, CCl₄-treated group; Con, control group; Apaf-1, apoptotic protease activating factor 1; TUNEL, terminal deoxynucleotidyl transferase deoxyuridinetriphosphate nick end labelling.

Figure 7. Breviscapine reduces oxidative stress in the livers of mice induced with CCl₄. (A) Liver SOD activity, GSH levels, MDA levels and H₂O₂ levels were measured. (B) Western blot analysis was used to determine SOD1, NQO-1, HO-1 and Nrf2 protein expression levels in the liver tissue samples. (C) p-p38, p-ERK1/2 and p-JNK protein levels in liver samples were calculated using western blot assays. Values are expressed as the mean ± standard error of the mean (n=8). **P<0.01 and ***P<0.001 vs. Con; *P<0.05; **P<0.01 and ***P<0.001 vs. CCl₄-induced mice. Mod, CCl₄-treated group; Con, control group; SOD, superoxide dismutase; GSH, glutathione synthase; MDA, malondialdehyde; HO-1, heme oxygenase 1; NQO-1, NAD(P)H quinone dehydrogenase 1; p-ERK, phosphorylated extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; Nrf2, nuclear factor erythroid 2-related factor 2.

Figure 8. Breviscapine reduces apoptosis the liver of mice treated with CCl₄. (A) TUNEL analysis was used to assess apoptosis in CCl₄-induced livers in mice after Breviscapine administration. Scale bar, 100 µm. (B) Apaf-1 positive cells were calculated in the liver sections of mice. Scale bar, 100 µm. Values are expressed as the mean ± standard error of the mean (n=10). ***P<0.001 vs. Con; ++P<0.01 and +++P<0.001 vs. CCl₄-induced mice. Mod, CCl₄-treated group; Con, control group; Apaf-1, apoptotic protease activating factor 1; TUNEL, terminal deoxynucleotidyl transferase deoxyuridinetriphosphate nick end labelling.
the presence or absence of breviscapine at 20 or 40 µM. The pro-inflammatory cytokines TNF-α, IL-6, IL-1β and IL-18, and the chemokine MCP-1 were highly induced by LPS at the mRNA level, as indicated by RT-qPCR analysis. Breviscapine co-treatment reduced the mRNA levels of these factors, indicating that breviscapine exerted anti-inflammatory effects on liver cells (Fig. 8B). LPS markedly increased the protein levels of TLR4 and MyD88, which was markedly inhibited by breviscapine (Fig. 8C). In addition, LPS-induced increases in the levels of phosphorylated IKKα, IκBα and NF-κB (p65) phosphorylation were examined by immunoblotting analysis. Representative western blot images and quantified protein levels are provided. Values are expressed as the mean ± standard error of the mean (n=8). *P<0.05, **P<0.01 and ***P<0.001 vs. Con; +P<0.05, ++P<0.01 and +++P<0.001 vs. LPS group. LPS, lipopolysaccharide; Con, control group; p-NF-κB, phosphorylated nuclear factor-κB; IκBα, inhibitor of NF-κB; IKKα, IκB kinase α; TLR, Toll-like receptor; MyD88, myeloid differentiation primary response gene 88; TNF, tumor necrosis factor; IL, interleukin; MCP, monocyte chemoattractant protein.

Breviscapine reduces LPS-induced oxidative stress in L02 cells. In vivo, breviscapine exerted anti-oxidant effects to attenuate CCl4-induced liver injury. A further in vitro experiment was performed to confirm this result. As presented in Fig. 10A, the DCFH-DA assay revealed that LPS treatment induced massive ROS generation, which was inhibited by breviscapine. In addition, breviscapine restored the levels of SOD1, NQO-1, HO-1 and Nrf2, which were decreased in LPS-treated cells (Fig. 10B). However, phosphorylation of p38, ERK1/2 and JNK stimulated by LPS was markedly reduced by breviscapine in a dose-dependent manner (Fig. 10C). These results further confirmed that breviscapine exerted protective effects against liver injury through inhibiting ROS production.
Discussion

The liver is an essential organ, which is involved in a variety of activities, including the generation of blood clotting factors, bile acid secretion, destruction of bacteria in the blood and detoxification. Liver injury may be triggered by various factors, including microbes, drugs and xenobiotics, as well as metabolites in the liver (1-3,36). Previous studies have indicated that breviscapine has beneficial properties, such as anti-oxidant, anticancer and anti-degenerative effects (14-16). While breviscapine has been investigated in various diseases, the current knowledge regarding its protective effect against liver injury induced by CCl₄ is limited, and further study is required to elucidate the underlying mechanism. In the present study, histological analysis indicated that breviscapine attenuated CCl₄-induced liver cell injury. Masson staining further demonstrated that the collagen deposition caused by CCl₄ was significantly decreased by breviscapine. In addition, the fibrotic area caused by CCl₄ was reduced by breviscapine administration. Supplementation with breviscapine in CCl₄-induced mice attenuated liver injury, reduced fibrosis and improved hepatic function by reducing the CCl₄-associated increases in ALT and AST levels, which was in line with previous studies (37,38).

To identify the possible molecular mechanisms, including the signaling pathways involved, the inflammatory response was investigated. The inflammatory response has been reported as a pivotal process leading to organ injury under various stresses (39,40). As previously described, CCl₄ treatment induced acute liver injury, which was closely associated with inflammation by elevating pro-inflammatory cytokine secretion (41). In line with previous studies, the present study confirmed that the pro-inflammatory cytokines IL-1β, TNF-α, IL-18 and IL-6 were highly expressed in CCl₄-treated mice in vivo, as well as in LPS-induced L02 cells in vitro, which represents a major mechanism of liver injury. Of note, breviscapine administration significantly reduced the release of these cytokines, suggesting its role in ameliorating CCl₄-induced liver injury. The TLR4 signaling pathway has a vital role in various physiological and pathological processes, including CCl₄-induced liver injury. It has been demonstrated that TLR4 recruits specific adaptor molecules, including MyD88, to initiate downstream signaling events towards the phosphorylation of NF-κB, thereby inducing the release of pro-inflammatory...
cytokines (42,43). In addition, NF-κB has a central role in the inflammatory response and triggers the expression of crucial inflammatory genes. Furthermore, NF-κB is one of the key transcription factors in LPS-stimulated inflammation, which regulates various inflammatory mediators, including TNF-α, IL-18, IL-6 and IL-1β (44). The IKK complex is activated by LPS through the TLR4 signaling pathway and phosphorylates IκBα in the cytoplasm. Consequently, it undergoes proteasomal degradation, leading to NF-κB release from the IKK complex and its translocation into the nucleus to subsequently enhance the expression of targeting genes involved in the inflammatory response (45,46). Thus, downregulation of the NF-κB signaling pathway regulated by TLR4/MyD88 is one of the major targets to attenuate the inflammatory response and associated diseases. Similarly, the present study indicated that the TLR4/NF-κB signaling pathway was activated in vitro and in vivo by LPS or CCl₄. Accordingly, the phosphorylation of IKKα, IκBα and NF-κB was stimulated, contributing to the secretion of pro-inflammatory cytokines. Breviscapine obviously exerted a suppressive effect on the TLR4/NF-κB signaling pathway, which appears to be a major mechanism of its anti-inflammatory action.

Apoptosis is a process that is tightly regulated by specific genes, including several pro- and anti-apoptotic genes expressing homologous proteins of the Bcl-2 family, including Bcl-2 and Bax, which are known to have an important role in determining whether a cell undergoes apoptosis (47-50). Apoptosis may be induced via the mitochondrial pathway and the Bcl-2/Bax equilibrium regulates the mitochondrial apoptotic pathway (51). Bax is a typical pro-apoptotic protein in the cytosol, which may translocate to the mitochondria to induce apoptosis, while Bcl-2 is an anti-apoptotic protein that suppresses Bax-induced apoptosis (52). Bax activation stimulates caspase-3 and PARP cleavage through Apaf-1 stimulation. Consequently, the apoptotic response is induced, eventually leading to cell death (53,54). Western blot analysis indicated that Bax expression in the CCl₄-treated mice was upregulated compared with that in the control group, whereas Bcl-2 expression in the CCl₄-treated group was downregulated. Of note, co-treatment with breviscapine inhibited the increase of Bax expression and the decrease of Bcl-2 expression induced by CCl₄. Consequently, the higher caspase-3 and PARP cleavage caused by CCl₄ was suppressed by breviscapine administration. Therefore, these results indicated that breviscapine ameliorated CCl₄-induced liver cell apoptosis by modulating the expression of the apoptosis-associated molecules Bax and Bcl-2 to inhibit the caspase-3-dependent apoptotic signaling pathway. To the best of our knowledge, the present study was the first to indicate that breviscapine alleviates liver injury through suppression of apoptosis and oxidative stress. According to previous studies, an interaction between apoptosis and inflammation is involved in regulating the progression and development of various types of tumor (55,56). NF-κB is generally considered to be a survival factor that activates the expression of various anti-apoptotic genes, including Bcl-2, myeloid leukemia-1, Bcl extra-large protein and cellular (FADD-like IL-1β-converting...
enzyme)-inhibitory protein. Inhibition of NF-κB leads to downregulation of the NF-κB-regulated anti-apoptotic proteins, thereby promoting apoptotic cell death (57,58). As activation of NF-κB is a frequent event in cancer cells, it may be an attractive potential therapeutic target. However, NF-κB inhibition alone is not sufficient to induce apoptosis (59).

The elevation of cellular ROS is thought to cause various diseases and conditions, including diabetes, cardiovascular diseases, cancer and aging (60-62). CCl₄ causes severe liver cell damage via elevation of ROS, leading to necrosis and apoptosis to result in acute liver injury. It is evident that direct reduction of ROS levels and inhibition of the CCl₄-induced oxidative chain reaction are critical for the prevention and treatment of CCl₄-induced acute liver damage (63). Therefore, supplementation with anti-oxidants is beneficial for human health. According to a previous study, breviscapine exerted anti-oxidant effects in the livers of rats (64). The present study indicated that breviscapine reduced oxidative stress via enhancing anti-oxidants, including SOD1, NQO-1, HO-1 and Nrf2. ROS may affect the activity of MAPKs (p38, ERK1/2 and JNK), which are involved in important signaling pathways regulating cell proliferation, differentiation and death in response to a variety of stimuli. MAPKs also sense the cellular redox status and are common targets for ROS (34,35,65,66). In the present study, breviscapine de-activated MAPK signaling induced by CCl₄ and LPS in vivo and in vitro, respectively. Therefore, the breviscapine-mediated attenuation of liver injury was also linked to its suppression of oxidative stress, which was in line with the results of a previous study (67).

In conclusion, the present study indicated the potential protective effects of breviscapine against CCl₄-induced liver damage. The hepatoprotective effects of breviscapine depend on its ability to reduce the generation of ROS, as well as pro-inflammatory signalling and apoptosis through de-activation of TLR4/NF-κB, caspase-3/PARP and MAPK signaling. Overall, the present study provides evidence for the protective effects of breviscapine against CCl₄-induced liver injury and suggests breviscapine as a potential hepatoprotective agent to prevent oxidative liver damage.

Acknowledgements

Not applicable.

Funding

This work was supported by the Institutional Animal Care and Use Committee of the Beijing Chao-Yang Hospital (Beijing, China) (grant no. Yt20115713c).

Availability of data and materials

The datasets generated and analyzed in the present study are included in this published article.

Authors' contributions

YL, PW, XZ and YD contributed to the design of this study and performed the experiments. QH drafted the manuscript. All the authors read and approved the final manuscript.

Ethics and consent to participate

This work was approved by the Institutional Animal Care and Use Committee of the Beijing Chao-Yang Hospital (Beijing, China). The present study was conducted following the Guide for the Care and Use of Experimental Animals of the National Institutes of Health (NIH) from 1996 (20).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


